IP Library Granted Patent US 10,398,720
Granted Patent B2
US 10,398,720 · App. 15/648,055 · Granted Sep 3, 2019

Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis

Inventors: Feriel Hacini-Rachinel (Biot, FR); Emmanuel Vial (Nice, FR); André Jomard (Saint Vallier de Thiey, FR)
Assignee: GALDERMA SA
A61K31/7048A61K9/0014A61K9/06A61K31/365A61K47/02A61K47/10A61K47/12A61K47/14A61K47/183A61K47/26A61K47/32A61K47/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,398,720
App. No.
15/648,055
Granted
Sep 3, 2019
Kind
B2
Abstract

A method of treating and/or preventing atopic dermatitis is described. The method includes use of a compound of the avermectin family, possibly ivermectin, or a compound of the milbemycin family in a pharmaceutically acceptable carrier.

Claims (11)

1. A method for treating atopic dermatitis, the method comprising: topically applying to the skin of a human subject in need thereof a pharmaceutical composition comprising 0.003% ivermectin by weight, relative to the total weight of the composition.

2. The method as defined by claim 1 , wherein the human subject in need thereof is a pregnant woman, a child, or an infant.

3. The method as defined by claim 1 , wherein the pharmaceutical composition is in the form of an emulsion, a cream, a lotion, a gel, or a solution.

4. The method as defined by claim 2 , wherein the human subject in need thereof is a pregnant woman.

5. The method as defined by claim 2 , wherein the human subject in need thereof is a child.

6. The method as defined by claim 2 , wherein the human subject in need thereof is an infant.

7. The method as defined by claim 3 , wherein the pharmaceutical composition is in the form of an emulsion.

8. The method as defined by claim 3 , wherein the pharmaceutical composition is in the form of a cream.

9. The method as defined by claim 3 , wherein the pharmaceutical composition is in the form of a lotion.

10. The method as defined by claim 3 , wherein the pharmaceutical composition is in the form of a gel.

11. The method as defined by claim 3 , wherein the pharmaceutical composition is in the form of a solution.

Assignments (4)
CHANGE OF ADDRESS Recorded Jun 28, 2022
From: GALDERMA HOLDING SA
To: GALDERMA HOLDING SA
Reel/Frame 060541/0374 →
ASSET TRANSFER AGREEMENT Recorded Oct 3, 2021
From: GALDERMA S.A.
To: NESTLÉ SKIN HEALTH S.A.
Reel/Frame 057698/0295 →
CHANGE OF NAME Recorded Oct 3, 2021
From: NESTLÉ SKIN HEALTH S.A.
To: GALDERMA HOLDING SA
Reel/Frame 057698/0356 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2017
From: HACINI-RACHINEL, FERIEL; VIAL, EMMANUEL; JOMARD, ANDRÉ
To: GALDERMA SA
Reel/Frame 042989/0697 →
Priority Claims (1)
EP 13306633 · Nov 29, 2013 · regional
Continuity (2)
Continuation 15100302
Related Publication 20170304340A1 · Oct 26, 2017